Discover how Chroma is expanding our impact.

BOSTON and CAMBRIDGE, Mass. – December 11, 2024 – Chroma Medicine and Nvelop Therapeutics today announced their merger and subsequent launch of nChroma Bio (“nChroma” or “the company”) to redefine the future of genetic medicines. nChroma brings together potent epigenetic editing plus non-viral, programmable delivery to address key limitations in the field and expand the scope of treatable diseases. The merger results in an industry-leading company with a deeply experienced team. Jeff Walsh will serve as nChroma’s CEO and Jeff Marrazzo will serve as nChroma’s Chairman of the Board. Concurrent with the merger, nChroma also completed an oversubscribed $75 million…

Boston, September 16, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, presented new preclinical data demonstrating the potency of its optimized HBV-targeted epigenetic editor, CRMA-1001, in an oral presentation at the 2024 International HBV Meeting, held September 11-15 in Chicago. These data, along with data from an earlier generation HBV-targeted epigenetic editor, underscore the potential for CRMA-1001 to improve the rate of functional cures in patients with HBV. CRMA-1001 is designed to silence both covalently closed circular DNA (cccDNA) and integrated DNA at the level of transcription without cutting or nicking the DNA, permanently inactivating…

Boston, MA, September 3, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, presented new preclinical data demonstrating the potency, durability, and specificity of its PCSK9-targeted epigenetic editor in an oral presentation at the 2024 European Society of Cardiology Congress, held August 30-September 2 in London. The data showcase the potential best-in-class potency achievable in NHPs with Chroma’s optimized epigenetic editors. They also indicate the company’s epigenetic editing platform can effectively silence expression of PCSK9 in the liver, inducing durable reductions in low-density lipoprotein-cholesterol (LDL-C) levels without cutting or nicking the DNA. The PCSK9 gene actively promotes the degradation of…

Boston, MA, July 18, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Melissa J. Moore, Ph.D., to its Board of Directors. “Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines.” Currently serving as a Board Director and Scientific Advisory Board member for multiple biotechnology companies, Dr. Moore…